The story of Viagra and its creator , copyright, presents a fascinating picture for cautious investors. While the blockbuster drug initially fueled enormous profits , its protection has lapsed , leading to generic options flooding the landscape . This erosion in pricing presents a significant obstacle for copyright and any fund considering a large